Cohance Lifesciences Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹477 Cr −14.2% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
CL

Cohance Lifesciences Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Cohance Lifesciences Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹619Cr
−26.3% YoY
+13.7% QoQ
Net profit
₹8Cr
−92.9% YoY
−71.4% QoQ
Margin
15.94%
−11.3 pp YoY
−1.6 pp QoQ
Price₹463
Market cap₹16.4K Cr
P/E152.6

The short version

FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable. Growth is expected to return from the second half of FY27, with Q1 FY27 being weak in both revenue and EBITDA due to revenue schedules skewed towards H2 and cost pressures (Page 4).

From Cohance Lifesciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable.
  • Recovery order: API segment first, followed by CDMO and Specialty Chemicals.
  • Growth driven by execution on existing programs, customer conversions, reloads, and improved asset utilization.
  • Pipeline strengthened with 10 Phase 3 programs; 2 programs recently commercialized and others progressing well.
  • New molecule launches ongoing, with 4 commercial launches planned across FY26 and FY27.
  • Increase in customer base and diversification efforts underway to reduce dependency on a few molecules.
  • Expansion in ADC, oligonucleotide, and small molecule capabilities expected to drive future growth.

2 more points from Cohance Lifesciences Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Cohance Lifesciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Capex during FY26 was INR 2.15 billion, focused on ADC, oligonucleotides, manufacturing infrastructure, and quality systems.
  • Capex spend expected to be nearly INR 3 billion in FY27.
  • Investment ongoing in NJ Bio to support bioconjugation programs for Phase 1 and Phase 2; implementation expected to take about one year plus validation time, with recovery in over two years.

2 more points from Cohance Lifesciences Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cohance Lifesciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company reported an active and growing order book, especially in the Phase 1 and Phase 2 programs with strong quality customers.
  • The Phase 3 pipeline increased to 10 programs, with two programs progressing toward commercialization.
  • They experienced healthy reload conversion above 90% and good new business conversions with innovator pharma and biotech customers.
  • The CDMO business is focusing on expanding the customer base and onboarding later-phase projects to accelerate revenue recovery.

2 more points from Cohance Lifesciences Ltd's call on order book

Create a free account to keep reading this call

Cohance Lifesciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Cohance Lifesciences Ltd Q4 FY26 results — key figures

Cohance Lifesciences Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue619840-26.3%545+13.7%
Operating profit (EBITDA)99229-56.9%95+3.5%
Operating margin15.94%27.27%-11.3 pp17.51%-1.6 pp
Profit before tax20161-87.6%41-51%
Net profit (PAT)8117-92.9%29-71.4%
EPS (₹)0.514.73-89.2%0.96-46.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹477 Cr, net profit ₹2 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cohance Lifesciences Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cohance Lifesciences Ltd Q4 FY26 results?

FY27 growth expected to return from the second half, with Q1 being weak and Q2 stable. Growth is expected to return from the second half of FY27, with Q1 FY27 being weak in both revenue and EBITDA due to revenue schedules skewed towards H2 and cost pressures (Page 4).

What is Cohance Lifesciences Ltd share price analysis?

Cohance Lifesciences Ltd currently shows a neutral. The stock trades at a P/E of 152.6 with a market cap of ₹16,429 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cohance Lifesciences Ltd planning capital expenditure?

Capex during FY26 was INR 2.15 billion, focused on ADC, oligonucleotides, manufacturing infrastructure, and quality systems.

Keep Cohance Lifesciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.